What changed?

Retatrutide Research & Clinical Development Updates

A sourced timeline of research records and material development changes tracked by BACToBasics for Retatrutide. Research-publication dates and clinical-development event dates are labeled separately so they are not mistaken for the same type of update.

Open Retatrutide guideResearch LibraryDevelopment tracker

Tracked items

5

Research sources

2

Development entries

3

Latest recorded date

Sep 15, 2026

Latest development activity

Detailed TRIUMPH-2 Phase 3 presentation scheduled for EASD

Sep 15, 2026 · Program status · Phase 3

Lilly announced that detailed TRIUMPH-2 results in adults with obesity or overweight and type 2 diabetes will be presented at EASD on September 30, 2026. The company previously reported topline weight and A1C results; BACToBasics will treat the conference presentation as the next evidence-review point rather than recasting the preview announcement as a new efficacy readout.

Open source ↗

Latest research record by publication date

TRIUMPH-1 Phase 3 Results

Published 2026 · Human intervention · Industry Phase 3 report

Company-reported TRIUMPH-1 results provide late-stage human evidence for retatrutide and move the evidence base beyond early clinical development.

Open source ↗

Tracked timeline

Research and development record

Development changes are dated to the underlying milestone. Research-source entries use the study or source publication year currently stored in the Research Library; that year is not presented as the date BACToBasics added the record.

Development changeSep 15, 2026

Detailed TRIUMPH-2 Phase 3 presentation scheduled for EASD

Program status · Phase 3

Lilly announced that detailed TRIUMPH-2 results in adults with obesity or overweight and type 2 diabetes will be presented at EASD on September 30, 2026. The company previously reported topline weight and A1C results; BACToBasics will treat the conference presentation as the next evidence-review point rather than recasting the preview announcement as a new efficacy readout.

Open BACToBasics context →Eli Lilly Medical — TRIUMPH-2 results and presentation status ↗
Research sourcePublished 2026

TRIUMPH-1 Phase 3 Results

Human intervention · Industry Phase 3 report

Company-reported TRIUMPH-1 results provide late-stage human evidence for retatrutide and move the evidence base beyond early clinical development.

Open BACToBasics context →Eli Lilly and Company ↗
Development changeJun 26, 2023

Phase 2 obesity trial published

Trial readout · Phase 2

The randomized Phase 2 obesity trial was published online in the New England Journal of Medicine, establishing direct mid-stage human efficacy and safety evidence for retatrutide.

Open BACToBasics context →NEJM — retatrutide Phase 2 trial ↗
Research sourcePublished 2023

Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial

Human intervention · Phase 2 randomized trial

This randomized Phase 2 trial established direct human efficacy and safety evidence for retatrutide as a triple GIP, GLP-1, and glucagon receptor agonist.

Open BACToBasics context →New England Journal of Medicine ↗

Follow future Retatrutide changes

Following a compound creates a clean baseline from the updates currently known. When BACToBasics later records a new research source or material development change, the My Tools update badge can surface it as new for you.

Browse all compound updates →Research Library →Clinical Development →

BACToBasics provides educational research organization only. A development milestone does not predict future approval, and a research record does not establish that a compound is safe, effective, approved, or appropriate for use.